Who to call at NEUROCRINE BIOSCIENCES, INC., and when
Fundz watches for the moments NEUROCRINE BIOSCIENCES, INC. starts buying, and tells you who to reach.
- An alert the day NEUROCRINE BIOSCIENCES, INC. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at NEUROCRINE BIOSCIENCES, INC., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at NEUROCRINE BIOSCIENCES, INC.. With Fundz connected, it knows.
NEUROCRINE BIOSCIENCES, INC.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
www.neurocrine.comAI Executive Summary
AI-powered analysis of 8-K filing content
Neurocrine Biosciences announced the mutual termination of Chief Medical Officer Dr. Sanjay Keswani effective September 25, 2026, with Dr. Eiry W. Roberts, M.D. appointed as successor effective September 28, 2026. The company characterized this as a strategic leadership change to align medical direction with evolving business objectives.
Key Takeaways
Dr. Sanjay Keswani terminated as Chief Medical Officer effective immediately on September 25, 2026
Dr. Eiry W. Roberts, M.D. appointed as successor with effective date of September 28, 2026
2 more takeaways
Filing Overview
What This Means
NEUROCRINE BIOSCIENCES, INC. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.